Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Adalimumab Using a Matching-Adjusted Indirect Comparison

被引：0
|
作者：
Nash, Peter [1 ]
McInnes, Iain B. [2 ]
Mease, Philip J. [3 ,4 ]
Choy, Ernest H. [5 ,6 ]
Thom, Howard [7 ]
Kalyvas, Chrysostomos [8 ]
Gandhi, Kunal [9 ]
Mpofu, Shephard [10 ]
Jugl, Steffen [10 ]
机构：
[1] Univ Queensland, Dept Med, Brisbane, Qld, Australia
[2] Univ Glasgow, Glasgow, Lanark, Scotland
[3] Swedish Med Ctr, Seattle, WA USA
[4] Univ Washington, Seattle, WA 98195 USA
[5] Cardiff Univ, Sch Med, Rheumatol Sect, Cardiff, S Glam, Wales
[6] Cardiff Univ, CREATE Ctr, Div Infect & Immun, Cardiff, S Glam, Wales
[7] Univ Bristol, Bristol, Avon, England
[8] MAPI Grp, Houten, Netherlands
[9] Novartis Pharmaceut, E Hanover, NJ USA
[10] Novartis Pharma AG, Basel, Switzerland
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1738
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Comparative Effectiveness of Secukinumab and Adalimumab in Ankylosing Spondylitis as Assessed by Matching-Adjusted Indirect Comparison: An Analysis Based on Pivotal Phase 3 Clinical Trial Data
    Maksymowych, Walter
    Strand, Vibeke
    Nash, Peter
    Thom, Howard
    Karabis, Andreas
    Gandhi, Kunal
    Porter, Brian
    Jugl, Steffen
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 914 - 915
  • [32] INDIRECT COMPARISON OF ADALIMUMAB VERSUS ETANERCEPT FOR THE TREATMENT OF PSORIATIC ARTHRITIS
    Kirson, N.
    Rao, S.
    Birnbaum, H. G.
    Kantor, E.
    Wei, R.
    Cifaldi, M.
    VALUE IN HEALTH, 2011, 14 (03) : A129 - A130
  • [33] COMPARATIVE EFFECTIVENESS OF SECUKINUMAB AND ADALIMUMAB IN ANKYLOSING SPONDYLITIS AS ASSESSED BY MATCHING-ADJUSTED INDIRECT COMPARISON: AN ANALYSIS BASED ON ALL PIVOTAL PHASE 3 CLINICAL TRIAL DATA
    Maksymowych, W. P.
    Walsh, J.
    Thom, H.
    Kalyvas, C.
    Rosal, G. F.
    Porter, B.
    Gandhi, K.
    Jugl, S. M.
    VALUE IN HEALTH, 2017, 20 (09) : A935 - A935
  • [34] Comparative Effectiveness of Secukinumab and Adalimumab in Ankylosing Spondylitis As Assessed By Matching-Adjusted Indirect Comparison: An Analysis Based on All Pivotal Phase 3 Clinical Trial Data
    Maksymowych, Walter P.
    Strand, Vibeke
    Nash, Peter
    Thom, Howard
    Karabis, Andreas
    Gandhi, Kunal
    Porter, Brian
    Jugl, Steffen
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [35] Secukinumab versus adalimumab for psoriatic arthritis
    Thorley, Jennifer
    LANCET RHEUMATOLOGY, 2020, 2 (06): : E322 - E322
  • [36] Comparative Effectiveness of Secukinumab and Golimumab in Ankylosing Spondylitis: Assessed By Matching-Adjusted Indirect Comparison Using Pivotal Phase 3 Clinical Trial Data
    Maksymowych, Walter P.
    Choy, Ernest
    Yazici, Yusuf
    Walsh, Jessica A.
    Thom, Howard
    Kalyvas, Chrysostomos
    Fox, Todd
    Gandhi, Kunal
    Jugl, Steffen
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [37] COMPARATIVE EFFECTIVENESS OF SECUKINUMAB AND GOLIMUMAB IN ANKYLOSING SPONDYLITIS ASSESSED BY MATCHING-ADJUSTED INDIRECT COMPARISON USING PIVOTAL PHASE III CLINICAL TRIAL DATA
    Tahir, Hasan
    Maksymowych, Walter
    Choy, Ernest
    Yazici, Yusuf
    Walsh, Jessica
    Thom, Howard
    Kalyvas, Chrysostomos
    Fox, Todd
    Gandi, Kunal
    Jugl, Steffen
    RHEUMATOLOGY, 2018, 57
  • [38] COMPARATIVE EFFECTIVENESS OF SECUKINUMAB AND GOLIMUMAB IN ANKYLOSING SPONDYLITIS ASSESSED BY MATCHING-ADJUSTED INDIRECT COMPARISON USING PIVOTAL PHASE 3 CLINICAL TRIAL DATA
    Maksymowych, W.
    Choy, E.
    Yazici, Y.
    Walsh, J.
    Thom, H.
    Kalyvas, C.
    Fox, T.
    Gandhi, K.
    Jugl, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1301 - 1301
  • [39] COMPARATIVE EFFECTIVENESS OF SECUKINUMAB AND ADALIMUMAB IN ANKYLOSING SPONDYLITIS (AS) AS ASSESSED BY MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC): AN ANALYSIS BASED ON ALL PIVOTAL PHASE 3 CLINICAL TRIAL DATA
    Nash, P.
    Maksymowych, W.
    Strand, V
    Thom, H.
    Karabis, A.
    Gandhi, K.
    Porter, B.
    Jugl, S.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 38 - 38
  • [40] Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus Secukinumab and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis
    Maksymowych, Walter P.
    Thom, Howard
    Morup, Michael F.
    Taieb, Vanessa
    Willems, Damon
    Lyris, Nikos
    Gaffney, Karl
    RHEUMATOLOGY AND THERAPY, 2024, 11 (04) : 1023 - 1041
12345